

August 07, 2023

**The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427**

**The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS**

Dear Sir/Madam,

Sub: Outcome of Board meeting under Regulation 30 and 30(4) read with Para A & B of Part A of Schedule III of SEBI(LODR) Regulations, 2015 of the Company held today i.e August 07, 2023

This is furtherance to our intimation dated July 10, 2023, the Board of Directors at their meeting held today i.e. August 07, 2023, approved the following:

1. The Un-audited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2023.
2. The appointment of M/s. B S R and Co., Chartered Accountants (Firm Registration No. 128510W) as the Statutory Auditors of the Company for a period of five (5) consecutive years commencing from the conclusion of 17th Annual General Meeting till the conclusion of the 22nd Annual General Meeting of the Company, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
3. Appointment of M/s. Ernst &Young LLP as Internal Auditor of the Company.
4. The Board of Director's Report, Management Discussion and Analysis Report, Corporate Governance Report and Business Responsibility and Sustainability Report for the year ended March 31, 2023.
5. Approval of 17th AGM Notice and fixed cut-off date to determine the e-voting. The Annual General Meeting of the Company will be held on Friday, September 29, 2023.
6. Appointment of Kfin Technologies Limited (RTA) to facilitate the e-voting process and appointment of Ms. Rashida Adenwala Practicing Company Secretary as scrutinizer for e-voting.
7. The Company has made a strategic decision and launched various products in the Retail trading of medicines and general items segment under its own brand name. These are provided through a membership model at a discount. The company will continue to explore opportunities to increase its product base under its own brand name. This could have an impact on our business, financial condition and results or operations.



8. Allotment of 46,478 Equity Shares to the employees of the Company and its subsidiary Companies. The detailed disclosure under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 is being sent separately.


Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Limited Review Report received from B S R & Associates LLP, the Statutory Auditors of the company the Unaudited Standalone and Consolidated Financial Results as mentioned at serial nos. 1 is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 03:30 PM and concluded at 6.10 PM.

Kindly take note of the same. The above information is also available on the Company's website.

For MedPlus Health Services Limited


Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS-7460



Encl: a/a

7/8/2023

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing,
6th Floor, Unit-3, Sy No. 83/1, Plot No. 02,
Raidurg, Hyderabad – 500 081 – India
Tel: +91 407 182 2000
Fax: +91 407 182 2399

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2023 ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited Review Report (Continued)

MedPlus Health Services Limited

7. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 2,478.28 million, total net profit after tax (before consolidation adjustments) of Rs. 13.46 million and total comprehensive income (before consolidation adjustments) of Rs. 13.46 million for the quarter ended 30 June 2023, as considered in the Statement. These interim financial results have been reviewed by other auditor whose report have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.


8. The Statement includes the interim financial results of 9 subsidiaries which have not been reviewed, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 1,080.79 million, total net profit after tax (before consolidation adjustments) of Rs. 18.18 million and total comprehensive income (before consolidation adjustments) of Rs. 18.18 million for the quarter ended 30 June 2023, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231WW-100024



Arpan Jain

Partner

Hyderabad

07 August 2023

Membership No.: 125710

UDIN:23125710BGYBRP4461

Limited Review Report (Continued)
MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	MHS Pharmaceuticals Private Limited	Subsidiary
4	Nova Sud Pharmaceuticals Private Limited	Subsidiary
5	Wynclark Pharmaceuticals Private Limited	Subsidiary
6	Kalyani Meditimes Private Limited	Subsidiary
7	Clearancekart Private Limited	Subsidiary
8	Sai Sridhar Pharma Private Limited	Subsidiary
9	Venkata Krishna Enterprises Private Limited	Subsidiary
10	Shri Banashankari Pharma Private Limited	Subsidiary
11	Deccan Medisales Private Limited	Subsidiary
12	Sidson Pharma Distributors Private Limited	Subsidiary
13	MedPlus Insurance Brokers Private Limited	Subsidiary




MedPlus Health Services Limited
CIN - L85110TG2006PLC051845

Regd. Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037.
Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2023

(Rs. in Millions)

S.No.	Particulars	Quarter ended			Year ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		Unaudited	Audited (refer note 4)	Unaudited	Audited
	Income				
	Revenue from operations	12,842.96	12,529.82	9,936.54	45,575.76
	Other income	93.93	136.94	101.30	460.78
I	Total income	12,936.89	12,666.76	10,037.84	46,036.54
	Expenses				
	Cost of materials consumed	99.07	89.27	49.35	258.80
	Purchases of stock-in-trade	10,419.44	10,155.41	8,128.31	37,529.32
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(409.58)	(544.87)	(344.26)	(2,211.24)
	Employee benefits expense	1,475.98	1,485.89	1,179.55	5,451.29
	Finance costs	232.71	222.69	198.10	830.27
	Depreciation and amortisation expense	524.15	558.00	380.98	1,815.56
	Other expenses	544.61	527.83	397.15	1,890.91
II	Total expenses	12,886.38	12,494.22	9,989.18	45,564.91
III	Profit before tax (I-II)	50.51	172.54	48.66	471.63
	Tax expense				
	- Current tax	29.26	94.76	11.00	180.53
	- Deferred tax (benefit) / expenses	(16.40)	(187.81)	0.87	(209.95)
IV	Total tax expense / (benefit)	12.86	(93.05)	11.87	(29.42)
V	Profit after tax (III-IV)	37.65	265.59	36.79	501.05
	Other Comprehensive Income (OCI)				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain / (loss) on employee defined benefit plan	-	(0.32)	37.69	4.61
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.06)	(9.19)	(1.27)
VI	Other comprehensive (loss) / income for the period/year, net of tax	-	(0.38)	28.50	3.34
VII	Total comprehensive income for the period/year (V+VI)	37.65	265.21	65.29	504.39
VIII	Profit for the period/year attributable to:				
	Shareholders of the Company	37.86	265.82	32.01	497.63
	Non-controlling interest	(0.21)	(0.23)	4.78	3.42
		37.65	265.59	36.79	501.05
IX	Total comprehensive income attributable to:				
	Shareholders of the Company	37.86	265.44	60.51	500.97
	Non-controlling interest	(0.21)	(0.23)	4.78	3.42
		37.65	265.21	65.29	504.39
X	Paid-up Capital				
	Equity Share Capital	238.61	238.61	238.60	238.61
XI	Other Equity				14,673.17
XII	Earnings per equity share (for the period/year not annualised)				
	Basic (In absolute Rs.)	0.32	2.24	0.27	4.17
	Diluted (In absolute Rs.)	0.32	2.24	0.27	4.17
XIII	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00

17



Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2023. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2023	Unutilised amount as on June 30, 2023*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	374.03	737.00
Total	5,782.73	5,045.73	737.00

* The aforesaid unutilised proceeds of Rs. 737.00 million have been placed as fixed deposits with bank.

3. The Board of Directors of the Company, at their meeting held on 10 January 2023, have approved a Scheme of amalgamation (Scheme) between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, with an appointed date of 1 April 2023. The management is in the process of filing the Scheme with the National Company Law Tribunal and other regulators for their approval.
4. The Consolidated figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
5. During the quarter and year ended 31 March 2023, based on the assessment of the future taxable profitability of its subsidiary, Optival Health Solutions Private Limited, the Group had recognized deferred tax assets on unexpired portion of tax incentive available u/s 80JJAA amounting to Rs.97.39 million
6. During the quarter and year ended 31 March 2023, the Chief Operating Decision Maker of the Group has carried out necessary change in the composition of its reportable segments. The said exercise has resulted in the Group identifying two reportable segments, i.e. (i) Retail trading of medicines and general items, and (ii) Diagnostic services. The comparative information as presented in the consolidated segment information have been restated to this effect in accordance with Ind AS 108.
7. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited

G.Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: August 07, 2023

**Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter ended June 30, 2023**

(Rs. In Millions)

Particulars	Quarter Ended			Year Ended
	June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
	Unaudited	Audited (refer note 4)	Unaudited (refer note 6)	Audited
1. Segment Revenue				
a. Retail	12,701.88	12,408.89	9,905.07	45,268.70
b. Diagnostic Services	138.99	119.41	31.47	305.54
c. Others	2.09	1.52	-	1.52
Revenue from Operations	12,842.96	12,529.82	9,936.54	45,575.76
2. Segment Results Profit				
a. Retail	106.96	196.28	64.17	590.34
b. Diagnostic Services	(95.64)	(82.34)	(70.56)	(294.50)
c. Others	(0.04)	(0.87)	0.00	(0.93)
Total	11.28	113.07	(6.39)	294.91
Less:				
Unallocable Finance cost	0.00	0.00	0.00	0.00
Add:				
Unallocable Other Income	39.23	59.47	55.05	176.72
Total profit before tax	50.51	172.54	48.66	471.63
3. Segment assets				
a. Retail	24,367.88	23,029.62	21,097.81	23,029.62
b. Diagnostic Services	1,790.61	1,719.85	990.93	1,719.85
c. Unallocated	2,351.16	3,217.71	3,367.74	3,217.71
Total	28,509.65	27,967.18	25,456.48	27,967.18
4. Segment liabilities				
a. Retail	12,648.13	12,118.54	10,629.91	12,118.54
b. Diagnostic Services	863.48	932.44	519.83	932.44
c. Unallocated	12.32	11.19	6.60	11.19
Total	13,523.93	13,062.17	11,156.34	13,062.17

9



B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing,
6th Floor, Unit-3, Sy No. 83/1, Plot No. 02,
Raidurg, Hyderabad – 500 081 – India
Tel: +91 407 182 2000
Fax: +91 407 182 2399

Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Associates LLP


Limited Review Report (Continued)
MedPlus Health Services Limited

contains any material misstatement.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231W/W-100024



Arpan Jain

Partner

Hyderabad

07 August 2023

Membership No.: 125710

UDIN:23125710BGYBRN6465

MedPlus Health Services Limited

CIN - L85110TG2006PLC051845


Regd. Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037.

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2023

(Rs. in Millions)

S.No	Particulars	Quarter ended		Year ended	
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		Unaudited	Audited (refer note 5)	Unaudited	Audited
	Income				
	Revenue from operations	718.92	869.48	272.85	2,139.26
	Other income	18.07	25.42	53.67	162.39
I	Total income	736.99	894.90	326.52	2,301.65
	Expenses				
	Cost of materials consumed	99.00	89.14	49.14	257.77
	Purchases of stock-in-trade	422.24	545.22	161.11	1,314.91
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.34)	21.87	(18.40)	(3.96)
	Employee benefits expense	97.58	98.53	48.96	281.45
	Finance costs	20.79	20.48	12.48	65.45
	Depreciation and amortisation expense	55.37	53.26	25.39	153.07
	Impairment reversals (net)	-	(69.44)	-	(69.44)
	Other expenses	82.20	69.96	47.44	226.54
II	Total expenses	771.84	829.02	326.12	2,225.79
III	Profit / (Loss) before tax (I-II)	(34.85)	65.88	0.40	75.86
	Tax expense				
	- Current tax	-	8.81	-	20.42
	- Deferred tax	-	-	-	-
IV	Total tax expense	-	8.81	-	20.42
V	Net Profit / (Loss) after tax (III-IV)	(34.85)	57.07	0.40	55.44
	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain / (loss) on employee defined benefit plan	-	(3.68)	1.17	(3.56)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
VI	Other comprehensive income / (loss) for the period / year, net of tax	-	(3.68)	1.17	(3.56)
VII	Total comprehensive income / (loss) for the period / year (V+VI)	(34.85)	53.39	1.57	51.88
VIII	Paid-up Capital				
	Equity Share Capital	238.61	238.61	238.60	238.61
IX	Other Equity				11,174.17
X	Earnings / (Loss) per equity share (for the period/year not annualised)				
	Basic (In absolute Rs.)	(0.29)	0.15	0.00	0.46
	Diluted (In absolute Rs.)	(0.29)	0.15	0.00	0.46
XI	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00

②



Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2023. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:


(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2023	Unutilised amount as on June 30, 2023*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	374.03	737.00
Total	5,782.73	5,045.73	737.00

* The aforesaid unutilised proceeds of Rs. 737.00 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. The Board of Directors of the Company, at their meeting held on 10 January 2023, have approved a Scheme of amalgamation (Scheme) between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, with an appointed date of 1 April 2023. The management is in the process of filing the Scheme with the National Company Law Tribunal and other regulators for their approval.
5. The standalone figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
6. During the quarter and year ended 31 March 2023, the Company recognised provision for impairment of its investments and loans receivable (including interest) from Kalyani Meditimes Private Limited, a Subsidiary, to the tune of Rs.56.33 million. The Company, during the said period, has also reversed impairment provision made during the prior periods to the tune of Rs.125.77 million in respect of investments in another subsidiary, WynClark Pharmaceuticals Private Limited. These amounts were recorded/reversed pursuant to management assessment of the future cash flows of the underlying subsidiary Companies and their historic and projected profitability.
7. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited


G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: August 07, 2023